Loading...
Loading...
CASI Pharmaceuticals, Inc.
CASI Pharmaceuticals, Inc.. Spoken Alpha tracks CASIF's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks CASIF's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters but stock falls 70% of the time
SampleWhen a company consistently beats but the stock doesn't react, consensus is usually set too low or the buy-side number is materially above sell-side. Watch for guidance walk-downs ahead of the print.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for CASIF.
curl https://api.spokenalpha.com/v1/companies/CASIF| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $6.14 | $4.22 | +45.6% | -0.2% | +2.6% |
| Q4 FY2026 | $6.12 | $4.34 | +40.9% | -0.4% | +2.6% |
| Q3 FY2026 | $6.04 | $4.26 | +41.9% | -6.4% | -4.5% |
| Q2 FY2026 | $6.51 | $4.42 | +47.2% | +1.1% | +2.7% |
| Q1 FY2025 | $6.39 | $4.46 | +43.2% | -7.6% | -8.2% |
| Q4 FY2025 | $6.53 | $4.50 | +45.1% | +3.2% | +2.0% |
| Q3 FY2025 | $6.36 | $4.53 | +40.3% | -3.7% | -3.3% |
| Q2 FY2025 | $6.47 | $4.62 | +40.0% | -4.0% | -2.1% |
| Q1 FY2024 | $6.07 | $4.46 | +36.2% | -3.3% | -4.8% |
| Q4 FY2024 | $6.64 | $4.58 | +45.0% | +0.2% | -2.5% |